An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Running, not enrolling

Conditions studied: Juvenile Idiopathic Arthritis

In brief

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Key facts

Study ID

NCT01357668

Run by

Bristol-Myers Squibb

People needed

800

Starts

2013-01-30

Expected to finish

2029-01-02

Last updated by the study team

2025-09-25

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of JIA (any subtype)
• Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
• Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial
• Parent or legally acceptable representative willing to participate in the study and sign the informed consent

You may not qualify if…

• Pregnant or nursing female at the time of enrollment
• Prior malignancies if the patient has not been malignancy free for at least 5 years.
• Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
• Known poor compliance with clinic visits (based on physician judgment).

Where it is running

• Local Institution - 0001 — Princeton, New Jersey, United States
• Local Institution - 0059 — Cincinnati, Ohio, United States
• Local Institution - 0025 — Bregenz, Austria
• Local Institution - 0002 — Innsbruck, Austria
• Local Institution - 0032 — Vienna, Austria
• Local Institution - 0010 — Botucatu, São Paulo, Brazil
• Local Institution - 0026 — Campinas, São Paulo, Brazil
• Local Institution - 0028 — São Paulo, São Paulo, Brazil
• Local Institution - 0027 — Rio de Janeiro, Brazil
• Local Institution - 0029 — Calgary, Alberta, Canada
• Local Institution - 0011 — Montreal, Quebec, Canada
• Local Institution - 0035 — Aarhus, Central Jutland, Denmark
• Local Institution - 0012 — Copenhagen, Denmark
• Local Institution - 0040 — Clermont-Ferrand, Puy-de-Dôme, France
• Local Institution - 0005 — Paris, France
• Local Institution - 0041 — Toulouse, France
• Local Institution - 0003 — Bad Bramstedt, Germany
• Local Institution - 0030 — Berlin, Germany
• Local Institution - 0034 — Freiburg im Breisgau, Germany
• Local Institution - 0031 — Hamburg, Germany
• Local Institution - 0033 — Heidelberg, Germany
• Local Institution - 0016 — Thessaloniki, Greece
• Local Institution - 0017 — Budapest, Hungary
• Local Institution - 0014 — Jerusalem, Israel
• Local Institution - 0060 — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.